The bill aims to amend patent infringement laws relating to biological products and the Medicare Improvement Fund. It proposes a limitation on the number of patents that can be asserted in an infringement action, especially for reference and application products. The bill also outlines specific requirements and conditions under which such limitations can be increased. Furthermore, it specifies the applicability of these amendments to applications submitted under the Public Health Service Act on or after the bill's enactment date. These proposed changes seek to address concerns related to patent infringement in the realm of biological products and their approvals under the Medicare Improvement Fund.